New vaccine trial targets aggressive brain cancer
NCT ID NCT05283109
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a vaccine made from small protein pieces (peptides) designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. The study includes 24 adults with newly diagnosed, untreated glioblastoma that has a specific genetic marker. The main goal is to check the vaccine's safety and find the right dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Preston Robert Tisch Brain Tumor Center at Duke University
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Targeted antibody may boost brain cancer treatment after incomplete surgery
- Experimental brain tumor cocktail targets recurrent glioma
- Blood tests could reveal hidden clues in aggressive brain cancer
- Brain cancer breakthrough? new trial delivers drug straight to tumor
- Surgical flap may open door to better brain tumor treatment